Relay Therapeutics, Inc. (RLAY) shareholders
Close on Nov 17, 2026Market cap $3.61BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (10.00%) | 21,270,751 | 10.00% | 13G (passive) amendment | Jul 31, 2026 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (6.40%), Perceptive Life Sciences Master Fund, Ltd. (6.40%) | 14,106,187 | 6.40% | 13G (passive) amendment | Jun 30, 2026 |
| Point72 Asset Management, L.P. Joint filing with Point72 Capital Advisors, Inc. (7.80%), Steven A. Cohen (7.80%) | 13,445,704 | 7.80% | 13G (passive) amendment | Jun 30, 2025 |
| Michael Kramarz Joint filing with Commodore Capital LP (7.80%), Commodore Capital Master LP (7.80%) and 1 more | 13,350,000 | 7.80% | 13G (passive) amendment | Jun 30, 2025 |
| Eli Casdin Joint filing with Casdin Capital, LLC (7.50%), Casdin Partners Gp, LLC (7.50%) and 1 more | 13,003,574 | 7.50% | 13G (passive) amendment | Dec 31, 2025 |
| Casdin Capital, LLC Joint filing with Casdin Partners Gp, LLC (7.50%), Eli Casdin (7.50%) and 1 more | 13,003,574 | 7.50% | 13G (passive) amendment | Dec 31, 2025 |
| Robert Egen Atkinson Joint filing with Commodore Capital LP (5.50%), Commodore Capital Master LP (5.50%) and 1 more | 12,000,000 | 5.50% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 10,308,012 | 6.10% | 13G (passive) amendment | Mar 31, 2025 |
| Commodore Capital Master LP Joint filing with Commodore Capital LP (5.80%) | 10,000,000 | 5.80% | 13G (passive) | May 8, 2025 |
| Point72 Capital Advisors, Inc. Joint filing with Point72 Asset Management, L.P. (5.70%), Steven A. Cohen (5.70%) | 9,694,217 | 5.70% | 13G (passive) | Mar 14, 2025 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%) | 438,471 | 9.99% | 13G (passive) | Apr 6, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RLAY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sb Investment Advisers (Uk) Ltd | 27,904,963 | 12.73% | $522.10M | – | 6.81% |
| FMR LLC | 20,110,113 | 9.18% | $376.26M | +16,414,682 | 0.02% |
| Casdin Capital, LLC | 16,035,240 | 7.32% | $300.02M | +1,616,666 | 15.02% |
| BlackRock, Inc. | 15,288,202 | 6.98% | $286.04M | +2,312,903 | 0.00% |
| Perceptive Advisors LLC | 14,106,187 | 6.44% | $263.93M | +4,355,046 | 3.96% |
| Commodore Capital LP | 12,000,000 | 5.48% | $224.52M | −5,000,000 | 13.37% |
| State Street Corp | 10,125,381 | 4.62% | $189.47M | +3,891,836 | 0.01% |
| Vanguard Capital Management LLC | 8,964,423 | 4.09% | $167.72M | +1,576,958 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 7,708,507 | 3.52% | $144.23M | +5,783,569 | 0.01% |
| Nextech Invest, Ltd. | 6,776,506 | 3.09% | $126.79M | +1,250,000 | 6.02% |
| Bellevue Group AG | 6,185,970 | 2.82% | $115.74M | −1,609,272 | 2.44% |
| Geode Capital Management, LLC | 4,726,576 | 2.16% | $88.45M | +1,215,940 | 0.00% |
| TCG Crossover Management, LLC | 4,273,356 | 1.95% | $79.95M | – | 1.92% |
| Alliancebernstein L.P. | 4,095,600 | 1.87% | $40.75M | +3,950,349 | 0.01% |
| Morgan Stanley | 3,851,071 | 1.76% | $72.05M | +2,419,068 | 0.00% |
| Siren, L.L.C. | 3,650,000 | 1.67% | $68.29M | New | 1.38% |
| Goldman Sachs Group Inc | 3,408,701 | 1.56% | $63.78M | +866,840 | 0.01% |
| Westfield Capital Management Co LP | 3,343,496 | 1.53% | $62.56M | New | 0.20% |
| Kynam Capital Management, LP | 3,300,000 | 1.51% | $61.74M | +1,875,741 | 3.41% |
| Dimensional Fund Advisors LP | 3,127,564 | 1.43% | $58.53M | +187,028 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 258 | 247M | 100.0% | 51 / 115 | 64 / 31 | 83M | 21M |
| Q1 2026 | 244 | 185M | 84.5% | 51 / 96 | 53 / 30 | 44M | 24M |
| Q4 2025 | 227 | 174M | 79.4% | 50 / 68 | 57 / 20 | 23M | 16M |
| Q3 2025 | 199 | 167M | 76.0% | 20 / 63 | 63 / 26 | 11M | 15M |
| Q2 2025 | 208 | 171M | 78.2% | 36 / 72 | 56 / 34 | 26M | 22M |
| Q1 2025 | 207 | 167M | 76.4% | 36 / 73 | 59 / 24 | 23M | 15M |
| Q4 2024 | 199 | 164M | 74.8% | 43 / 87 | 36 / 37 | 26M | 31M |
| Q3 2024 | 195 | 169M | 77.3% | 46 / 72 | 46 / 28 | 56M | 8M |
| Q2 2024 | 179 | 132M | 60.3% | 22 / 75 | 50 / 30 | 12M | 18M |
| Q1 2024 | 189 | 138M | 63.1% | 31 / 73 | 50 / 19 | 20M | 15M |
| Q4 2023 | 177 | 134M | 61.2% | 33 / 55 | 57 / 25 | 19M | 16M |
| Q3 2023 | 172 | 130M | 59.5% | 23 / 67 | 47 / 12 | 9M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
260 funds held RLAY in Q2 2026, 48% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RLAY | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 6,800,083 | 3.10% | $127.23M | 0.01% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 6,304,701 | 2.88% | $117.96M | 1.10% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,163,646 | 1.90% | $77.90M | 0.09% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,943,788 | 0.89% | $36.37M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 1,917,750 | 0.88% | $36.11M | 0.41% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 1,850,700 | 0.84% | $34.85M | 1.58% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,840,896 | 0.84% | $34.44M | 0.29% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,767,834 | 0.81% | $33.29M | 0.10% | Jul 31, 2026 |
| Harbor Small Cap Growth Fund | 1,681,000 | 0.77% | $31.65M | 1.19% | Jul 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 1,680,415 | 0.77% | $31.64M | 0.43% | Jul 31, 2026 |
| Select Health Care Portfolio | 1,680,000 | 0.77% | $23.60M | 0.41% | May 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,574,152 | 0.72% | $29.45M | 0.20% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,366,611 | 0.62% | $25.57M | 0.26% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,285,400 | 0.59% | $18.06M | 0.01% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,128,810 | 0.52% | $21.12M | 0.14% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sanjiv Patel | President and CEO, Director | 1,358,204 | 0.62% | Oct 8, 2026 |
| Donald A. Bergstrom | President, R&D | 396,878 | 0.18% | Oct 30, 2026 |
| Thomas Catinazzo | Chief Financial Officer | 103,665 | 0.05% | Oct 30, 2026 |
| Peter Rahmer | See remarks | 222,904 | 0.10% | Oct 30, 2026 |
| Brian Adams | Chief Legal Officer | 371,472 | 0.17% | Jul 30, 2025 |
| Alexis Borisy | Director | 234,175 | 0.11% | Jun 10, 2026 |
| Mark Murcko | Director | 996,952 | 0.45% | Jun 10, 2026 |
| Claire Mazumdar | Director | – | – | Jun 10, 2026 |
| Habib J. Dable | Director | – | – | Jun 10, 2026 |
| Linda A. Hill | Director | – | – | Jun 10, 2026 |
| Lonnel Coats | Director | – | – | Jun 10, 2026 |
| Douglas S. Ingram | Director | 25,000 | 0.01% | Jun 10, 2026 |
| Sekar Kathiresan | Director | – | – | Jun 6, 2025 |
| Jami Rubin | Director | 67,242 | 0.03% | Jun 6, 2025 |
| Vision Fund (Aiv M2) L.P. Softbank | 10% owner | – | – | Aug 28, 2026 |
| Pauling (Cayman) Ltd SVF | 10% owner | 27,904,963 | 12.73% | Aug 28, 2026 |
| Investment Advisers (Uk) Ltd Sb | 10% owner | 21,904,963 | 10.00% | Aug 28, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Peter Rahmer See remarks | Oct 28, 2026 | Sale | −753 | $18.62 | $14.02K | 222,904 |
| Donald A. Bergstrom President, R&D | Oct 28, 2026 | Sale | −2,252 | $18.62 | $41.93K | 396,878 |
| Thomas Catinazzo Chief Financial Officer | Oct 28, 2026 | Sale | −1,469 | $18.62 | $27.35K | 103,665 |
| Sanjiv Patel President and CEO, Director | Oct 7, 2026 | Sale(10b5-1 plan) | −48,199 | $18.10 | $872.40K | 471,301 |
| Thomas Catinazzo Chief Financial Officer | Oct 6, 2026 | Sale(10b5-1 plan) | −206 | $19.26 | $3.97K | 105,134 |
| Thomas Catinazzo Chief Financial Officer | Oct 6, 2026 | Sale(10b5-1 plan) | −17,511 | $18.58 | $325.35K | 105,340 |
| Thomas Catinazzo Chief Financial Officer | Sep 8, 2026 | Sale(10b5-1 plan) | −17,717 | $18.94 | $335.56K | 122,851 |
| Donald A. Bergstrom President, R&D | Sep 8, 2026 | Sale(10b5-1 plan) | −8,530 | $18.97 | $161.81K | 399,130 |
| Sanjiv Patel President and CEO, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −48,199 | $18.94 | $912.89K | 519,500 |
| Peter Rahmer See remarks | Aug 26, 2026 | Sale(10b5-1 plan) | −4,508 | $20.03 | $90.30K | 223,657 |
| Investment Advisers (Uk) Ltd Sb 10% owner | Aug 25, 2026 | Sale | −6,000,000 | $19.40 | $116.40M | 21,904,963 |
| Sanjiv Patel President and CEO, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −48,199 | $20.33 | $979.89K | 567,699 |
| Thomas Catinazzo Chief Financial Officer | Aug 14, 2026 | Sale(10b5-1 plan) | −17,717 | $19.74 | $349.73K | 140,568 |
| Thomas Catinazzo Chief Financial Officer | Jul 28, 2026 | Sale | −1,459 | $18.61 | $27.15K | 158,285 |
| Donald A. Bergstrom President, R&D | Jul 28, 2026 | Sale | −2,237 | $18.61 | $41.63K | 407,660 |
| Peter Rahmer See remarks | Jul 28, 2026 | Sale | −748 | $18.61 | $13.92K | 228,165 |
| Sanjiv Patel President and CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −48,199 | $19.58 | $943.74K | 615,898 |
| Thomas Catinazzo Chief Financial Officer | Jul 6, 2026 | Sale(10b5-1 plan) | −17,717 | $18.69 | $331.13K | 159,744 |
| Donald A. Bergstrom President, R&D | Jul 6, 2026 | Sale(10b5-1 plan) | −8,660 | $18.71 | $162.03K | 409,897 |
| Sanjiv Patel President and CEO, Director | Jun 30, 2026 | Award | +3,056 | $6.95 | $21.24K | 664,097 |
| Peter Rahmer See remarks | Jun 30, 2026 | Sale(10b5-1 plan) | −50,000 | $19.09 | $954.50K | 225,857 |
| Peter Rahmer See remarks | Jun 30, 2026 | Award | +3,056 | $6.95 | $21.24K | 228,913 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −17,717 | $17.01 | $301.37K | 177,461 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Option exercise | +56,323 | $5.04 | $283.87K | 233,784 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −51,560 | $16.97 | $874.97K | 177,461 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Option exercise | +51,560 | $4.45 | $229.44K | 229,021 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −61,563 | $16.97 | $1.04M | 177,461 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Option exercise | +61,563 | $5.22 | $321.36K | 239,024 |
| Thomas Catinazzo Chief Financial Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −56,323 | $16.97 | $955.80K | 177,461 |
| Donald A. Bergstrom President, R&D | Jun 22, 2026 | Option exercise | +93,456 | $4.12 | $385.04K | 512,013 |
| Donald A. Bergstrom President, R&D | Jun 22, 2026 | Sale(10b5-1 plan) | −93,456 | $16.94 | $1.58M | 418,557 |
| Thomas Catinazzo Chief Financial Officer | May 14, 2026 | Sale(10b5-1 plan) | −17,717 | $12.86 | $227.84K | 195,178 |
| Donald A. Bergstrom President, R&D | Apr 28, 2026 | Sale | −1,490 | $14.79 | $22.04K | 418,557 |
| Peter Rahmer See remarks | Apr 28, 2026 | Sale | −753 | $14.79 | $11.14K | 275,857 |
| Thomas Catinazzo Chief Financial Officer | Apr 28, 2026 | Sale | −972 | $14.79 | $14.38K | 212,895 |
| Thomas Catinazzo Chief Financial Officer | Apr 9, 2026 | Option exercise | +1,800 | $5.22 | $9.40K | 215,667 |
| Thomas Catinazzo Chief Financial Officer | Apr 9, 2026 | Sale(10b5-1 plan) | −1,800 | $15.00 | $27.00K | 213,867 |
| Thomas Catinazzo Chief Financial Officer | Apr 7, 2026 | Sale(10b5-1 plan) | −17,717 | $13.01 | $230.50K | 213,867 |
| Thomas Catinazzo Chief Financial Officer | Mar 9, 2026 | Sale(10b5-1 plan) | −17,717 | $10.06 | $178.23K | 231,584 |
| Peter Rahmer See remarks | Jan 28, 2026 | Sale | −1,354 | $8.45 | $11.44K | 276,610 |
| Donald A. Bergstrom President, R&D | Jan 28, 2026 | Sale | −2,686 | $8.45 | $22.70K | 420,047 |
| Thomas Catinazzo Chief Financial Officer | Jan 28, 2026 | Sale | −1,695 | $8.45 | $14.32K | 249,301 |
| Peter Rahmer See remarks | Jan 27, 2026 | Sale | −11,684 | $7.62 | $89.03K | 277,964 |
| Donald A. Bergstrom President, R&D | Jan 27, 2026 | Sale | −18,895 | $7.62 | $143.98K | 422,733 |
| Thomas Catinazzo Chief Financial Officer | Jan 27, 2026 | Sale | −13,820 | $7.62 | $105.31K | 250,996 |
| Sanjiv Patel President and CEO, Director | Jan 6, 2026 | Sale | −43,168 | $7.82 | $337.57K | 661,041 |
| Peter Rahmer See remarks | Dec 31, 2025 | Award | +994 | $2.99 | $2.97K | 338,463 |
| Sanjiv Patel President and CEO, Director | Dec 31, 2025 | Award | +994 | $2.99 | $2.97K | 704,209 |
| Sanjiv Patel President and CEO, Director | Nov 3, 2025 | Sale | −62,073 | $7.00 | $434.51K | 703,215 |
| Peter Rahmer See remarks | Oct 29, 2025 | Sale | −21,394 | $7.50 | $160.46K | 337,469 |
| Thomas Catinazzo Chief Financial Officer | Oct 28, 2025 | Sale | −21,664 | $7.29 | $157.93K | 313,631 |
| Peter Rahmer See remarks | Oct 28, 2025 | Sale | −19,135 | $7.29 | $139.49K | 358,863 |
| Donald A. Bergstrom President, R&D | Oct 28, 2025 | Sale | −30,897 | $7.29 | $225.24K | 521,823 |
| Brian Adams Chief Legal Officer | Jul 29, 2025 | Sale | −18,276 | $3.68 | $67.26K | 371,472 |
| Thomas Catinazzo Chief Financial Officer | Jul 29, 2025 | Sale | −18,380 | $3.68 | $67.64K | 335,295 |
| Peter Rahmer See remarks | Jul 29, 2025 | Sale | −15,724 | $3.68 | $57.86K | 377,998 |
| Donald A. Bergstrom President, R&D | Jul 29, 2025 | Sale | −26,701 | $3.68 | $98.26K | 552,720 |
| Brian Adams Chief Legal Officer | Jul 28, 2025 | Sale | −1,637 | $3.74 | $6.12K | 389,748 |
| Thomas Catinazzo Chief Financial Officer | Jul 28, 2025 | Sale | −1,701 | $3.74 | $6.36K | 353,675 |
| Peter Rahmer See remarks | Jul 28, 2025 | Sale | −1,359 | $3.74 | $5.08K | 393,722 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Relay Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 440,875 shares on Oct 13, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Sanjiv Patel Director, Officer | Oct 7, 2026 | 96,401 | $1.81M | Oct 7, 2026 | Restricted Stock Units |
| Thomas Catinazzo Officer | Oct 6, 2026 | 93,153 | $1.81M | Oct 6, 2026 | Restricted and Performance Stock Units |
| Peter Rahmer Officer | Aug 26, 2026 | 50,000 | $1.03M | Aug 26, 2026 | Restricted Stock Units |
| Pauling (Cayman) Ltd SVF Stockholder | Aug 25, 2026 | 6,000,000 | $123.42M | Aug 25, 2026 | Acquired upon the automatic conversion of Series C Convertible Preferred Stock upon the closing of the Issuer's initial public offering. The shares were acquired and fully paid for in December 2018. |
| Sekar Kathiresan Director | Aug 4, 2026 | 42,225 | $826.47K | Aug 4, 2026 | Stock Option Exercise |
| Sekar Kathiresan Director | Jul 31, 2026 | 30,000 | $563.55K | Jul 31, 2026 | Stock Option Exercise |
| Sekar Kathiresan Director | Jul 21, 2026 | 30,000 | $594.41K | Jul 21, 2026 | Stock Option Exercise |
| Sekar Kathiresan Director | Jul 20, 2026 | 66,055 | $1.29M | Jul 20, 2026 | Stock Option Exercise |
| Sanjiv Patel Director, Officer | Jul 7, 2026 | 144,597 | $2.73M | Jul 7, 2026 | Restricted Stock Units |
| Peter Rahmer Officer | Jun 30, 2026 | 50,000 | $987.00K | Jun 30, 2026 | Performance Stock Units |
| Thomas Catinazzo Officer | Jun 22, 2026 | 204,880 | $3.25M | Jun 22, 2026 | Exercise of Stock Options |
| Donald A. Bergstrom Officer | Jun 22, 2026 | 110,646 | $1.76M | Jun 22, 2026 | Exercise of Stock Options |
| Thomas Catinazzo Officer | May 14, 2026 | 37,234 | $492.23K | May 14, 2026 | Restricted and Performance Stock Units |
| Thomas Catinazzo Officer | Mar 9, 2026 | 53,151 | $525.66K | Mar 9, 2026 | Restricted Stock Units |
| Peter Rahmer Officer | Oct 29, 2025 | 21,394 | $160.44K | Oct 29, 2025 | Restricted Stock |
Congress trades
1 trade in Relay Therapeutics reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Daniel Goldman NY10 | Sold | Jul 12, 2023 | $1K–15K | Aug 13, 2023 |
See a number that looks wrong?